MENU
JUN 17, 2020 7:30 AM PDT

Advanced solutions for viral detection and immune monitoring

Sponsored by: Fluidigm
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Assistant Member, Arthritis and Clinical Immunology Director of Translational Informatics, Clinical Resources, Biorepository and Human Phenotyping Cores, Oklahoma Medical Research Foundation
    Biography
      Joel Guthridge, PhD is an Assistant Member of the Arthritis and Clinical Immunology Program at the Oklahoma Medical Research Foundation where his is also the Director of the Translational Informatics, Human Phenotyping and the CAP certified OMRF Biorepository. His research centers on mechanisms of lupus disease and understanding the molecular basis of the heterogeneity of lupus disease manifestations. Dr. Guthridge is the Co-PI of the Accelerating Medicines Partnership in SLE and RA, Tissue Resources Group as part of the AMP SLE/RA Leadership Center. The Human Phenotyping and Biorepository Cores at OMRF are also NIH funded through NIAMS Rheumatic Disease Resources Cores Center and NIGMS/IDeA Center for Research Translation funding. Dr. Guthridge's previous positions included management of the informatics and high-throughput screening groups at Univera Pharmaceuticals, Evolutionary Genomics and Dharmacon. Prior to this, he was an Instructor in the Department of Medicine, Division of Rheumatology at the University of Colorado Health Sciences Center with a focus on complement regulation and regulatory protein structure and function.
    • Associate Professor and consultant physician Science for Life Laboratory, Karolinska Institutet Department of Pediatric Rheumatology, Karolinska University Hospital, Stockholm
      Biography
        Petter Brodin is a pediatrician at the Karolinska University Hospital and an immunologist at Science for Life Laboratory (SciLifeLab). His lab combines state-of-the-art experimental methods and computational tools to monitor human immune systems as comprehensively as possible. Recently Dr. Brodin was appointed Swedish coordinator for the international COVID Human Genetic Effort consortium. Its goal is to search for possible inborn errors of immunity in patients who require intensive care for COVID-19 despite being younger than 50 and having no underlying health conditions.

      Abstract

      Adapting Fluidigm’sMicrofluidic GE Platform for a Test for SARS-CoV-2 by Joel Guthridge, PhD

      In this talk, we present our experiences in the rapid development and deployment of a SARS-CoV-2 high-throughput screening platform. This platform utilizes the microfluidics solutions from Fluidigm to expand testing in Oklahoma and surrounding states.  Our OMRF Human Phenotyping Core has had a longstanding relationship with Fluidigm, starting with the C1 single cell solutions and BiomarkHD/Juno platforms for targeted transcriptomic and SNP variant analyses. This interaction further expanded in November of 2019 to include the Hyperion/Helios platforms for suspension cell and tissue mass cytometry. Over  an approximate 4 week period beginning in late March, OMRF scientists have worked closely with Fluidigm’s R&D group from the Microfluidics Division and the clinical staff at the University of Oklahoma Health Sciences Center and Medical Centers to refine the use of the IDT CDC SARS-CoV-2 assay on the Fluidigm Juno/BiomarkHD RT-qPCR gene expression platform expanding testing options. This collaborative arrangement enabled the rapid build-out of laboratory space, relocation of equipment and re-training of personnel on the Fluidigm equipment, integration of robotic solutions for key repetitive error-prone steps, deployment of a custom LIMS suitable for high-throughput screening deployment in a CLIA/CAP High-Complexity Laboratory environment and validation of the IDT CDC SARS-CoV-2 assay on the Fluidigm platform.  The Oklahoma COVID-19 PCR Test EUA application filed with the FDA by the third week of the collaboration and is pending FDA approval. However, testing of screening samples has started and is expected to ramp up to over 2,000 samples per day in the current configuration. Limitations are only due to logistical constraints (space, data collection/reporting issues. We will discuss our vision for the scalability of this platform within the CLIA/CAP clinical laboratory environment for the expanding testing needed in the Midwestern region of the US.

      Systems-level immune dynamics from acute to recovery phase of severe COVID-19 by Petter Brodin, MD, PhD

      Severe COVID-19 is characterized by dramatic immune system activation and inflammation. Several studies to modulate the immune response and limit immunopathology are ongoing. To better understand the natural course of severe COVID-19, we have applied systems-level immune monitoring of 39 COVID-19 patients, sampling them up to 12 times from admission through intensive care and recovery. These studies have revealed several modules of coregulated cell populations and coordinated changes in plasma protein levels. The studies describe a shared trajectory during the course of the disease. We have also found a previously unappreciated role of eosinophils during the course of disease, and we investigated the determinants of productive antibody responses.

      Learning Objectives:

      1. Learn what solutions and offerings Fluidigm can provide to advance COVID-19 research

      2. Learn how customers are using our solutions to advance COVID-19 research


      Show Resources
      You May Also Like
      JUN 17, 2020 1:30 PM PDT
      C.E. CREDITS
      JUN 17, 2020 1:30 PM PDT
      Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
      JAN 23, 2020 9:00 AM PST
      C.E. CREDITS
      JAN 23, 2020 9:00 AM PST
      DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
      JUN 17, 2020 12:00 PM PDT
      C.E. CREDITS
      JUN 17, 2020 12:00 PM PDT
      The 2020 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to rage. While PCR-based assays are used for viral diagnosis, high through-put, rapid s...
      JUN 17, 2020 10:30 AM PDT
      C.E. CREDITS
      JUN 17, 2020 10:30 AM PDT
      COVID 19 has resulted in diverse research needs ranging from mechanism and impact of the disease, to solutions to identify, combat or treat the disease. Cellular technologies such as flow an...
      FEB 19, 2020 11:00 AM PST
      C.E. CREDITS
      FEB 19, 2020 11:00 AM PST
      DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
      MAY 13, 2020 8:00 AM PDT
      C.E. CREDITS
      MAY 13, 2020 8:00 AM PDT
      Provide education on COVID-19 disease and SARS-CoV-2. Review the types of tests used for the diagnosis of infectious diseases. Discuss approaches to serologic test development. Review the ki...
      Loading Comments...
      Show Resources
      Attendees
      • See more